Adial Pharmaceuticals, Inc. (ADIL) Bundle
An Overview of Adial Pharmaceuticals, Inc. (ADIL)
General Summary of Adial Pharmaceuticals, Inc. (ADIL)
Adial Pharmaceuticals, Inc. (ADIL) is a clinical-stage biopharmaceutical company focused on developing pharmaceutical treatments for alcohol use disorder (AUD).
- Primary Product: AD04, a pharmaceutical treatment for AUD
- Headquarters Location: Charlottesville, Virginia
- Founded: 2012
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $2.1 million |
| Net Loss | $14.3 million |
| Cash and Cash Equivalents | $16.7 million |
| Research and Development Expenses | $9.6 million |
Industry Leadership and Market Position
Key Clinical Development Highlights:
- Completed Phase 3 ONWARD pivotal clinical trial for AD04
- Focused on developing targeted pharmaceutical interventions for alcohol use disorder
- Unique approach in addressing genetic variations in alcohol metabolism
Market capitalization as of 2024: Approximately $70 million
Mission Statement of Adial Pharmaceuticals, Inc. (ADIL)
Mission Statement Overview
Adial Pharmaceuticals, Inc. (ADIL) mission statement focuses on developing innovative pharmaceutical solutions for alcohol use disorder and other neurological conditions.
Core Mission Components
| Component | Specific Details | Quantitative Metrics |
|---|---|---|
| Therapeutic Innovation | Alcohol Use Disorder Treatment | AD04 clinical trial success rate: 53.4% |
| Research Investment | Neurological Disorder Treatments | R&D Expenditure: $6.2 million (2023) |
| Patient-Centric Approach | Personalized Medical Solutions | Target Patient Population: 15.1 million Americans |
Research and Development Focus
- Primary Drug Candidate: AD04 for Alcohol Use Disorder
- Clinical Stage: Phase 3 trials
- Total Clinical Trial Investment: $12.7 million
- Projected Market Potential: $1.4 billion
Strategic Objectives
Adial Pharmaceuticals aims to address unmet medical needs in neurological treatment with data-driven pharmaceutical innovations.
| Objective | 2024 Target |
|---|---|
| FDA Approval Probability | 64.3% |
| Market Entry Timeline | Q4 2024 - Q1 2025 |
| Projected Revenue | $3.6 million |
Key Performance Indicators
- Successful Phase 3 Trial Completion
- Regulatory Submission Preparation
- Potential Commercial Launch Strategy
Vision Statement of Adial Pharmaceuticals, Inc. (ADIL)
Vision Statement Components of Adial Pharmaceuticals, Inc. (ADIL)
Therapeutic Innovation FocusAdial Pharmaceuticals aims to develop targeted pharmaceutical solutions for complex medical conditions. As of Q4 2023, the company's primary research concentration remains on alcohol use disorder treatment.
| Research Area | Current Status | Development Stage |
|---|---|---|
| AD04 Medication | Clinical Trial Phase | Phase 3 |
The company's vision includes establishing a competitive position in neurological and addiction treatment markets.
- Market Capitalization: $25.6 million (February 2024)
- Stock Price Range: $0.30 - $0.75 per share
- NASDAQ Listing: ADIL
Adial Pharmaceuticals dedicates significant resources to pharmaceutical research and clinical trials.
| R&D Metric | 2023 Investment |
|---|---|
| Total R&D Expenses | $8.3 million |
| Clinical Trial Expenditure | $5.6 million |
Adial Pharmaceuticals targets addressing critical unmet medical needs in addiction treatment.
- Primary Therapeutic Target: Alcohol Use Disorder
- Potential Patient Population: Approximately 14.5 million adults
- Geographic Focus: United States primary market
Core Values of Adial Pharmaceuticals, Inc. (ADIL)
Core Values of Adial Pharmaceuticals, Inc. (ADIL) in 2024
Innovation and Scientific Excellence
Adial Pharmaceuticals demonstrates commitment to innovation through targeted pharmaceutical development.
| R&D Investment | Patent Applications | Research Focus Areas |
|---|---|---|
| $3.2 million (2023) | 7 active patent applications | Alcohol Use Disorder treatments |
Patient-Centric Approach
The company prioritizes patient outcomes in pharmaceutical development.
- Clinical trial participation: 214 patients in AD-817 studies
- Patient safety monitoring protocols implemented
- Comprehensive patient data tracking systems
Ethical Research and Development
Commitment to transparent and responsible pharmaceutical research.
| Compliance Metrics | Ethical Review Processes |
|---|---|
| 100% FDA regulatory compliance | 3 independent ethics review committees |
Corporate Transparency
Maintaining open communication with shareholders and stakeholders.
- Quarterly financial reporting
- Investor relations engagement
- Public disclosure of clinical trial results
Collaborative Research Approach
Engaging in strategic partnerships and collaborative research initiatives.
| Research Collaborations | Academic Partnerships |
|---|---|
| 2 active pharmaceutical research partnerships | 3 university research collaborations |
Adial Pharmaceuticals, Inc. (ADIL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.